Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
Obviously it is always pleasing when AVCT share price is on the rise............ but I am slightly conflicted also because it has to mean that @120p it means the open offer @95p is going to be fully taken up, so I won't get the number of excess shares I would like...... but hey ho still a very rosey outlook. Mayt...
Mr Adventure
"Nah, selling get funds to pay for more Offer shares at 95."
think you might be right. I am applying for another 7000 excess shares @95p from cash I hold. Can't really see a downside on applying for as many as possible with SP currently @111p. Might offload the remaining dead duck fracking shares I hold to finance some more. Mayt
Garonne - I believe Escala asked where you got the info that AFC were being hosted by Advanced Forming Research Centre. I also would like to see where you found this interesting piece of info.
However I don't see it as the negative that you naturally confer in your usual early morning whinge. I notice from the AFRC site that among scores of other companies they have Boeing and Rolls Royce as partners, and Siemens are also members. So even if AFC were hosted by AFRC, why is that something to moan about? Maytal
Layla1
I agree with you about how BOD are playing this, and trying to keep our heads down - not becoming a target. Definitely need to adopt the Zen approach as investors, and try not to wet our knickers, with every news item we read - alternatively there is always the exit door. Mayt
Kevin
I think they are just stating the facts as they know them, that Doxorubicin market will be £1.38bn in 2024. Of course Doxorubicin is only one of a series of Anthracyclines Chemo drugs, and I imagine that if the AVCT product proves a success, it will more than likely increase Doxorubicin market share, and also likely encourage other similar Chemo drugs to find a similar solution - with AVCT in an attractive position.
All supposition, but think that the £1.38Bn is very much a minimum figure based on current Doxorubicin market share expectation without our product. Mayt
Kevin-
When the RNS states "use is limited" I am pretty sure it means use of "doxorubicin", which is not our product being tested. Our product will mitigate the toxicity of doxorubicin, and allow it to be used in a more targeted and less toxic way.
That is what I understand anyway.. and not that use of "our" product is "limited".
Mayt